Here, Dr. Pedram Razavi explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients. A new study seeks to anticipate the malignant cells' next move, like playing poker with cancer and being able to see most of its cards. Learn more: bit.ly/47cxyDZ

Congratulations to this year’s recipients of the MSK 2025 Paul Marks Prize for Cancer Research: Dr. @oawlab.bsky.social, of MSK; Dr. Andrea Ablasser, of EPFL; and Dr. Christina Curtis, of @stanfordmedicine.bsky.social. Learn more about the winners: bit.ly/47y8HLb

Important translational and clinical work here using CD40 agonistic antibody in metastatic cancer @anatosaurus.bsky.social Cancer Cell www.cell.com/cancer-cell/... @mskcancercenter.bsky.social @mskdeptofmed.bsky.social

We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List. bit.ly/4nefIFv

MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases. Learn more ⬇️

Excited to announce a new publication from our @mskcancercenter.bsky.social Histiocytosis group identifying a predictor for impaired response to MEK inhibition in histiocytosis patients and potential for ERK inhibition. Out today in @Cancer_Cell. www.sciencedirect.com/science/arti...

We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at MSK, has been elected to the @nam.edu. With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition. Congratulations, Dr. Abdel-Wahab! bit.ly/49ezKw0

#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social ➡️ bit.ly/3JncnWA

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:

This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/47h3DJG

At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/4nafnUa

Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation. @mskcancercenter.bsky.social Learn more: bit.ly/3KZ0iHw

At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author. 🗓️ October 19, 9:25 a.m. CEST Learn more: bit.ly/4n5B8od

Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/3W74yY3

Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/3WcyfH5

Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social Learn more: bit.ly/42JM3ws

Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/3W6rqqz

Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social Learn more: bit.ly/4neLsu1 🗓️ October 18 | 11:10 a.m. CEST

Congratulations to Ross Levine on his new role as @mskcancercenter.bsky.social's Chief Scientific Officer!

Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social Learn more: bit.ly/4qrq3Rg

This case study underscores the emerging potential of noninvasive prenatal testing (NIPT), a technology developed to screen for fetal conditions but now being studied for its ability to detect cancer. Learn more ⬇️

🎥 At #SOHO2025, Ariela Noy of @mskcancercenter.bsky.social shared insights into the management of Burkitt #lymphoma, highlighting the need to improve frontline treatment. Watch here: 👉 buff.ly/kp1MrVH 👈 #LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky @societyofhemonc.bsky.social

Join us for MSK's 2025 Health Equity in Cancer Care Conference on Friday, November 14. This complimentary one-day event will unite experts from across fields, institutions, and specialties to explore actionable strategies for advancing #healthequity in underserved populations.

Cancer research means bigger breakthroughs, on a faster timeline, that improve the lives of people impacted by cancer. Today is World Cancer Research Day & all donations will be DOUBLED. Donate today & help bring more possibilities to families facing cancer. bit.ly/46mefYy #WorldCancerResearchDay

Radiation therapy for prostate cancer is more precise, convenient, and personalized than ever before. From #SBRT to MRI-guided and adaptive approaches, MSK experts are leading advances that improve outcomes and protect quality of life for patients with #prostatecancer. ⬇️

At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm 🗓️ Saturday, September 20 | 9:20 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm 🗓️ Friday, September 19 | 9:40 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma. 🗓️ Thursday, September 18 | 4:40 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma. 🗓️ Wednesday, September 17 | 12:14 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm 🗓️ Wednesday, September 17 | 11:10 a.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Starting TODAY! Join @greatdebates.bsky.social and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer. @mskcancercenter.bsky.social #crcsm #GIcancer See the full agenda 📖: bit.ly/48g13pf

🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V

Happening Tuesday, 9/9 at #WCLC25: MSK's Dr. Alexis Chidi will discuss how deep learning-based CT analysis enhances #lungcancer risk prediction in never smoking women. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social Tuesday, 9/9 | 10 a.m. CEST More: bit.ly/45XeCZq

Happening Tuesday, 9/9 at #WCLC25: MSK's Dr. David Jones will discuss perioperative modalities for resectable non small cell #lungcancer. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social l Tuesday, 9/9 | 1 p.m. CEST Learn more: bit.ly/3V3O8iD

We're counting down the days until #ASH25 in December! ⏰Don't miss the scientific workshops taking place on the Friday before the meeting. @ash.hematology.org @mskcancercenter.bsky.social

At #WCLC25, our #RadOnc colleague Jennifer Ma will present a retrospective review of intrathoracic radiotherapy to treat #HPV-associated head and neck #squamouscellcarcinoma metastases. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social September 9 | 3 p.m. CEST ➡️ bit.ly/4mUWZ2m

Tomorrow morning, #lungcancer expert Mark Kris will discuss clinicopathologic features of TP53/RB1-mutant squamous cell lung cancers at #WCLC25. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social September 8 | 10:30 a.m.. CEST ➡️ bit.ly/41EZM7b

Coming up at #WCLC25: @mskcancercenter.bsky.social's Helena Yu will highlight diagnostic and treatment opportunities for #leptomeningealdisease in oncogene-driven non-small cell #lungcancer. #LCSM @iaslc.bsky.social September 7 | 3:53 p.m. CEST ➡️ bit.ly/4mOHBnV

Don't miss an opportunity to learn from the Chief of the Thoracic Oncology Service at @mskcancercenter.bsky.social! At #WCLC25, Mark Awad will share lessons about work-life balance in high-stress medical careers. #LCSM @iaslc.bsky.social September 7 | 1:45 p.m. CEST ➡️ bit.ly/3HTNpxr

Happening Monday, 9/8 at #WCLC25: MSK pathologist Dr. Natasha Rekhtman will discuss optimizing front-line treatment for small cell #lung cancer. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social 📆: September 8 at 5 p.m. CEST Learn more: bit.ly/4mXBiig

Out now in @cp-trendsbiochem.bsky.social: "PTMs as Molecular Encoders: Reprogramming Chaperones into Epichaperomes for Network Control in Disease" from @chiosislabmskcc.bsky.social. Learn more ⬇️

Happening tomorrow at #WCLC25: @mskcancercenter.bsky.social's @charlesrudin.bsky.social will highlight future directions in small cell #lungcancer research. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social September 6 | 10:30 a.m. CEST ➡️ bit.ly/3HJJmnp

At MSK, Clinical Nurse Specialists (CNS) are making a significant impact on patient outcomes through their expert guidance, evidence-based interventions, & compassionate leadership. This #CNSWeek, we honor their dedication to advancing care and improving lives. Help celebrate our MSK CNSs below! 🎉

Results of a pilot study led by investigators at @mskcancercenter.bsky.social showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @markgeyermd.bsky.social Learn more: bit.ly/4mFwo9q

Congrats to Rastko Rakočević of the Pulmonary Service on receiving a certificate of excellence for presenting a top abstract in a plenary session at #AABIP2025! He presented research on robotic-assisted #bronchoscopy for biopsy of primary #lungcancers. @mskcancercenter.bsky.social

Breast medical oncologist and early drug development specialist @breastcancerdoc.bsky.social discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field of #breastcancer on @emjreviews.bsky.social lastest podcast. 🎙️ Listen here: bit.ly/422CWXd

www.youtube.com/watch?v=7JOT... Found this great video of #DrMichaelPostow explaining potential of predicting #immunotherapy response with imaging! @mskcancercenter.bsky.social #ShortTakesInOncology #peer2peermd

New FDA-approved blood test "Shield" offers a less invasive #colorectal cancer screening, but while Shield may detect later-stage cancers, it misses over one-third of stage 1 cancers and most precancerous polyps. Learn more about what MSK experts have to say about Shield. ⬇️ #cansky

Introducing a new, high-yield CME program @mskcancercenter.bsky.social designed to streamline preparation for the ABIM certification & recertification exams in Medical Oncology. Registration is complimentary for all fellows. Learn more: bit.ly/MedOncReview2025 #MSKAcceleratedMedOncReview